Merck: acquires Themis

(CercleFinance.com) - Merck & Co has announced that it has reached a final agreement to acquire Themis, an unlisted company specializing in vaccines and immune modulating therapies for infectious diseases and cancer.
The terms of the deal were not specified.

The pharmaceutical company explained that this acquisition should accelerate the development of the Themis experimental vaccine for Covid-19, a vaccine in a preclinical development phase, for which clinical studies should start later in 2020.

In connection with this acquisition, Merck has signed a memorandum of understanding with Institut Pasteur and the CEPI reflecting their commitment to treating the Covid-19 pandemic by offering a vaccine at an affordable price worldwide.


Copyright (c) 2020 CercleFinance.com. All rights reserved.